Episode 4 - Opening the CAR(T) Door to Get Your Patients to Therapy

Estimated Time
0.50 hr

Release Date
Apr 08, 2022

Expiration Date
Apr 08, 2023

Description
Opening the CAR(T) door to get your patients to therapy, the final episode of the 4-part educational initiative The Evolving Role of CAR T-cell Therapy for R/R B-cell Lymphomas: Improving Access and Outcomes, is designed for community-based oncology clinicians. This CE activity includes conversations among CAR-T experts and a community clinician; it includes patient video clips and numerous downloadable resources including a directory of CAR-T treatment centers organized by state.
 
This activity focuses on improving access to CAR-T therapy for patients regardless of geography or socioeconomic status, including common misperceptions, how to overcome barriers including financial ones, and the need for earlier referral.
 
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated.

For pharmacists, Medical Learning Institute, Inc. will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

Speakers

Accreditation and Disclosure Information

Target Audience
This CE activity is intended for hematologists-oncologists, fellows, NPs, PAs, nurses, pharmacists, navigators, case managers engaged in the care of patients with R/R B-cell lymphomas.
 
Educational Objectives
After completing this CE activity, the participant should be better able to:
  • Recognize common misperceptions regarding access to CAR-T
  • Refer patients for consultation to determine if they are candidates for CAR-T earlier in the treatment journey
  • Identify and use resources to improve patients’ access to CAR-T
Accreditation, Support and Credit
Joint LogoIn support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and The Leukemia & Lymphoma Society.   Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
 
 
Educational Partner Statement
This activity is developed with our educational partner, The Leukemia & Lymphoma Society.
 
Support Statement
This CE activity is supported through an educational grant from Bristol Myers Squibb.
 
Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 0.5 contact hour(s) and no contact hour(s) in the area of pharmacology.
 
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
 
Universal Activity Number: JA0007322-9999-22-030-H01-P
Type of Activity: Knowledge
 
AAPA Credit Designation Statement
AAPA LogoMedical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 4/8/2023. PAs should only claim credit commensurate with the extent of their participation.
 
 
 
 
 
CCMC Contact Hours
PACE LogoThis program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board-certified case managers. This course is approved for 0.5 CE contact hour(s).
 
Activity code:  I00050209. Approval Number: 220001055. To claim these CEs, log into your CCMC Dashboard at www.ccmcertification.org.
 
Interprofessional Continuing Education (IPCE) Statement
IPCE LogoThis activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.
 
Disclosure & Conflict of Interest Policy
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education.  To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity. 
 
Faculty Disclosures
 
Planner/Presenter
Sergio A. Giralt, MD, FACP
Melvin Berlin Family Chair in Myeloma Research
Professor of Medicine
Weill Cornell Medical College
Deputy Head, Division of Hematologic Malignancies
Attending Physician, Adult BMT Service
Memorial Sloan Kettering Cancer Center
New York, NY
 
Sergio A. Giralt, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for Actinium Pharmaceuticals, Inc., Amgen, Bristol Myers Squibb, Celgene Corporation, GlaxoSmithKline, Jazz Pharmaceuticals, Janssen Pharmaceuticals, Omeros Corporation, Pfizer Inc., and Sanofi.
Research Grant from Actinium Pharmaceuticals, Inc, Amgen, Bristol Myers Squibb, Celgene Corporation, Janssen Pharmaceuticals, Omeros Corporation, Pfizer Inc., Sanofi, and Takeda Pharmaceutical Company.
 
Planner/Presenter
Sanjay K. Juneja, MD
Hematology, Medical Oncology
Chief of Oncology Line           
Baton Rouge General  Hospital
Mary Bird Perkins Cancer Center
Baton Rouge, LA
 
Sanjay K. Juneja, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for Gilead Sciences, Inc. and xCures.
Speakers’ Bureau with AstraZeneca Pharmaceuticals and Merck & Co., Inc.
Stock Ownership with Phenomune and xCures.
Independent Contractor for xCures.
 
Planner/Presenter
Rayne H. Rouce, MD, BS
Associate Professor
Department of Pediatrics
Texas Children’s Cancer Center for Cell and Gene Therapy
Baylor College of Medicine
Houston, TX
 
Rayne H. Rouce, MD, BS, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for Novartis Pharmaceuticals Corporation and Pfizer Inc.
Research Grant from Tessa Therapeutics.
 
Presenter
Neena Kennedy, BSN, RN, OCN™
Clinical Trial Nurse Navigator
The Leukemia & Lymphoma Society 
Rye Brook, NY

Neena Kennedy, BSN, RN, OCN, has no relevant financial relationship with ineligible companies to disclose for this educational activity. 

Presenter
Alejandro Marinos-Velarde, MD
Hematology-Oncology Fellow
Baylor College of Medicine
Houston, TX
 
Alejandro Marinos-Velarde, MD, has no relevant financial relationship with ineligible companies to disclose for this educational activity. 
 
Presenter
Elizabeth A. Weber, BSN, RN
Commercial Cellular Therapy Coordinator
University of Pennsylvania Health System
Philadelphia, PA
 
Elizabeth A. Weber, BSN, RN, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for Janssen Pharmaceuticals and Novartis Pharmaceuticals Corporation.

All of the relevant financial relationships of individuals for this activity have been mitigated.

Patient/Planner/Presenter
Laurie Adami
Laurie Adami has no relevant financial relationship with ineligible companies to disclose for this educational activity. 
 
Patient/Planner/Presenter
Sonia Su
Sonia Su has no relevant financial relationship with ineligible companies to disclose for this educational activity. 
 
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider and The Leukemia & Lymphoma Society, the joint provider do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
 
Planner
Lauren Berger, MPH
The Leukemia & Lymphoma Society
 
Lauren Berger, MPH, has a financial interest/relationship or affiliation in the form of:
Stock Ownership with Bristol Myers Squibb, Gilead Sciences, Inc., Merck & Co., Inc., Organon & Co., Pfizer Inc., and Viatris Inc.
 
All of the relevant financial relationships of individuals for this activity have been mitigated.
 
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
 
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
 
About This Activity
Medical Learning Institute, Inc. and The Leukemia and Lymphoma Society are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc. and The Leukemia and Lymphoma Society.
 
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.
 
 
Copyright © 2022 Medical Learning Institute, Inc | All Rights Reserved